{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:49:32Z","timestamp":1785437372296,"version":"3.56.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jtct.2022.04.001","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T01:43:56Z","timestamp":1649727836000},"page":"370.e1-370.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine\/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8789-3742","authenticated-orcid":false,"given":"Naveed","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9444-7046","authenticated-orcid":false,"given":"Ashish Arunkumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina Pires","family":"de Rezende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9978-4719","authenticated-orcid":false,"given":"Folashade","family":"Otegbeye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal Muhammad","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4441-9212","authenticated-orcid":false,"given":"Mariana Nassif","family":"Kerbauy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda W.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leland","family":"Metheny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saswat K.","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-0973","authenticated-orcid":false,"given":"Benjamin K.","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten M.","family":"Boughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucila","family":"Kerbauy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreza Feitosa","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Gallogly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mansur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Weltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7816-4828","authenticated-orcid":false,"given":"Rafick-Pierre","family":"Sekaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Hamerschlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.04.001_bib0001","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.04.001_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.bmt.1705207","article-title":"Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up","volume":"37","author":"Oyekunle","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.001_bib0003","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bbmt.2004.10.008","article-title":"Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation","volume":"11","author":"Wong","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.001_bib0004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.04.001_bib0005","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.001_bib0006","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.04.001_bib0007","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood.V97.11.3669","volume":"97","author":"Blaise","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.001_bib0008","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood.V83.9.2723.2723","article-title":"A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group","volume":"83","author":"Ringd\u00e9n","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.001_bib0009","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.bmt.1704198","article-title":"Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study","volume":"32","author":"Bunin","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.001_bib0010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1200\/JCO.2000.18.2.340","article-title":"Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia","volume":"18","author":"Davies","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.04.001_bib0011","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/0360-3016(95)00115-F","article-title":"Allogeneic marrow transplantation following cyclophosphamide and escalating doses of hyperfractionated total body irradiation in patients with advanced lymphoid malignancies: a Phase I\/II trial","volume":"32","author":"Demirer","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtct.2022.04.001_bib0012","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1182\/blood.V77.8.1660.1660","article-title":"Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens","volume":"77","author":"Clift","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.001_bib0013","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood.V76.9.1867.1867","article-title":"Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens","volume":"76","author":"Clift","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.001_bib0014","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.bbmt.2005.12.029","article-title":"A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission","volume":"12","author":"Marks","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.001_bib0015","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","article-title":"Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.001_bib0016","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.04.001_bib0017","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/bloodadvances.2018019976","article-title":"Conditioning intensity in secondary AML with prior myelodysplastic syndrome\/myeloproliferative disorders: an EBMT ALWP study","volume":"2","author":"Sengsayadeth","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.04.001_bib0018","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.04.001_bib0019","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bbmt.2015.10.024","article-title":"Myeloablative, but not reduced-intensity, conditioning overcomes the negative effect of flow-cytometric evidence of leukemia in acute myeloid leukemia","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.001_bib0020","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.bmt.1705278","article-title":"Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies","volume":"37","author":"Petropoulos","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.001_bib0021","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/sj.bmt.1704192","article-title":"A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma","volume":"32","author":"Einsele","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.001_bib0022","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1078-0432.CCR-10-1912","article-title":"Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma","volume":"17","author":"Somlo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2022.04.001_bib0023","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijrobp.2012.03.033","article-title":"Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"85","author":"Wong","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtct.2022.04.001_bib0024","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.bbmt.2017.01.067","article-title":"Phase I trial of total marrow and lymphoid irradiation transplantation conditioning in patients with relapsed\/refractory acute leukemia","volume":"23","author":"Stein","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.001_bib0025","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood-2010-06-288357","article-title":"Phase 1\/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies","volume":"117","author":"Rosenthal","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.001_bib0026","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.bbmt.2014.09.005","article-title":"Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine\/busulfan: a phase I study","volume":"20","author":"Patel","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.001_bib0027","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.bbmt.2017.04.002","article-title":"Dose escalation of total marrow irradiation in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Hui","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.001_bib0028","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/acm2.12742","article-title":"Organ sparing of linac-based targeted marrow irradiation over total body irradiation","volume":"20","author":"Warrell","year":"2019","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.jtct.2022.04.001_bib0029","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/153303460600500508","article-title":"Linac-based intensity modulated total marrow irradiation (IM-TMI)","volume":"5","author":"Aydogan","year":"2006","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.jtct.2022.04.001_bib0030","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ijrobp.2010.11.035","article-title":"Gwe-Ya K. Total marrow irradiation with RapidArc volumetric arc therapy","volume":"81","author":"Aydogan","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtct.2022.04.001_bib0031","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.001_bib0032","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.001_bib0033","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/sj.leu.2404335","article-title":"Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning","volume":"20","author":"Baron","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.04.001_bib0034","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.3389\/fimmu.2018.02832","article-title":"Atypical human effector\/memory CD4+ T cells with a naive-like phenotype","volume":"9","author":"Caccamo","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2022.04.001_bib0035","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0167-5699(00)01605-4","article-title":"CD27: a memory B-cell marker","volume":"21","author":"Agematsu","year":"2000","journal-title":"Immunol Today"},{"key":"10.1016\/j.jtct.2022.04.001_bib0036","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.exphem.2004.05.027","article-title":"Antitumor response of CD14+\/CD16+ monocyte subpopulation","volume":"32","author":"Szaflarska","year":"2004","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jtct.2022.04.001_bib0037","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1189\/jlb.0806510","article-title":"The CD14+CD16+ blood monocytes: their role in infection and inflammation","volume":"81","author":"Ziegler-Heitbrock","year":"2007","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jtct.2022.04.001_bib0038","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41409-018-0171-z","article-title":"Epidemiology and biology of relapse after stem cell transplantation","volume":"53","author":"Horowitz","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.001_bib0039","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.bbmt.2013.08.016","article-title":"Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Introduction","volume":"19","author":"Wayne","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.001_bib0040","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s41375-018-0257-z","article-title":"Cytogenetic and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care","volume":"32","author":"Dohner","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.04.001_bib0041","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3324\/haematol.2018.191536","article-title":"Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older","volume":"103","author":"Prassek","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.04.001_bib0042","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1200\/JCO.2009.22.2547","article-title":"Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia","volume":"27","author":"Rao","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.04.001_bib0043","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbmt.2017.09.019","article-title":"Total marrow lymphoid irradiation\/fludarabine\/melphalan conditioning for allogeneic hematopoietic cell transplantation","volume":"24","author":"Jensen","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.001_bib0044","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.bbmt.2016.07.006","article-title":"Fludarabine\/busulfan versus fludarabine\/melphalan conditioning in patients undergoing reduced-intensity conditioning hematopoietic stem cell transplantation for lymphoma","volume":"22","author":"Kekre","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.001_bib0045","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/s41409-020-0878-5","article-title":"Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT","volume":"55","author":"Peric","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2022.04.001_bib0046","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2019-121849","article-title":"Comparison of reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in non-Hodgkin lymphomas (NHL)-a Center for International Blood & Marrow Transplant Research (CIBMTR) analysis","volume":"134","author":"Ghosh","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.001_bib0047","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1182\/blood.V124.21.545.545","article-title":"RIC allo-SCT with Flu\/Bu in comparison to Flu\/Mel for AML results in similar overall survival: a report from the ALWP of the EBMT","volume":"124","author":"Baron","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.001_bib0048","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijrobp.2008.04.071","article-title":"Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation","volume":"73","author":"Wong","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtct.2022.04.001_bib0049","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2016-09-742049","article-title":"CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression","volume":"129","author":"Tarafdar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.001_bib0050","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF beta-FOXO signalling maintains leukaemia initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2022.04.001_bib0051","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.4049\/jimmunol.1400434","article-title":"Histone deacetylation critically determines T cell subset radiosensitivity","volume":"193","author":"Pugh","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2022.04.001_bib0052","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1038\/s41467-019-11906-2","article-title":"Tumor-reprogrammed resident T cells resist radiation to control tumors","volume":"10","author":"Arina","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2022.04.001_bib0053","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41590-018-0114-2","article-title":"Tissue-resident memory T cells at the center of immunity to solid tumors","volume":"19","author":"Amsen","year":"2018","journal-title":"Nat. Immunol"},{"key":"10.1016\/j.jtct.2022.04.001_bib0054","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.001_bib0055","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722011927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722011927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T23:47:30Z","timestamp":1726444050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722011927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2666636722011927"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.04.001","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine\/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}